Video

Giving Patients Autonomy During Difficult Conversations

Author(s):

Joshua Richter, M.D.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams, according to Joshua Richter, M.D., a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center.

The tool guided patients to rank their depression and anhedonia (inability to feel pleasure), and provided meaningful insight on patients who are ready to go to palliative care or end their treatment. End-of-life discussions are never easy, but this helped to give the patient more autonomy in the conversation.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of ronald.
June 25th 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
June 5th 2025

Being in the Present Moment With Multiple Myeloma

Ronald Chin
I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor.
Grace Allison, B.S.N., RN, OCN, RN-BC, and Erin Mensching, RN-B.S.N., OCN
May 18th 2025

Providing Care and Listening With Compassion During Cancer

Grace Allison, B.S.N., RN, OCN, RN-BC